Business Wire

CA-CONVIVA

9.9.2022 12:21:36 CEST | Business Wire | Press release

Share
Worldwide Streaming Market Achieves Double-digit Growth in Q2 2022; Smart TVs and Roku Dominate Global Viewing According to Conviva

Conviva, the global streaming analytics platform, released today the results of its quarterly State of Streaming Report, which shows continued growth in the global streaming market, including gains of (14%) in the second quarter of 2022 as compared to Q2 2021. Asia and Latin America saw the most growth — 90% and 70%, respectively — while North America, the most mature streaming market in the world, also grew 5% year over year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220909005099/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Conviva's State of Streaming Report Q2 2022 (Graphic: Business Wire)

As the global streaming industry matures, streaming success is getting more complicated. Device fragmentation is growing, and viewers’ quality expectations continue rising in concert with an ad-supported streaming world. Streaming publishers are challenged to deliver a consistent and positive experience. Whether in Africa using an Android phone or in Texas on a Smart TV – viewers expect a quality picture, instant access to content and zero glitches.

“The race is on to see which publishers will meet these expectations, including providing the best experience when it’s most important,” said Keith Zubchevich, President and CEO, Conviva. “Those who do will quickly eclipse the competition. Most importantly, those who make it a priority to obtain real-time actionable insights about their customers’ (real-world experiences) will undoubtedly separate the leaders from the pack,” added Zubchevich.

Key Findings

Bitrates are Rising

Conviva found bitrate rose globally in Q2 2022 across all screen types and devices, but often at the expense of other quality metrics. For example, Smart TVs saw the largest increase in bitrate of all screen types, up 15.1% year over year. However, to provide this more high-definition experience, Smart TVs saw noticeable increases in video start failures, video start time and buffering. Conversely, PlayStation and Roku were the only big screen devices to both decrease video start times (down 10.7% and 12% respectively) and increase bitrate (up 4.6% and 12.9% respectively).

Big Screens – and Roku – Remain on Top

Roku continued to hold the top spot among big screen devices (big screens include connected TVs, Smart TVs and gaming consoles), holding nearly steady at 30.5% of viewing time, down less than one percent as compared to Q2 2021 with Amazon Fire TV coming in second with 16% of big screen viewing time. Samsung TV (13.7%), Android TV (7.8%) and LG TV (7.3%) rounded out the top five devices for big screen viewing time. Chromecast, Xbox and PlayStation all saw a decrease in share as compared to the previous year.

Android vs iPhone Streaming Showdown

To date, the iPhone has been the primary device for mobile streaming, especially in North America. In Q2 2022 the gap closed, with iPhone and Android phones capturing nearly identical global market share, 35.8% vs 33.2% respectively. In addition, Android phones outpaced the iPhone by 10% in YoY growth in streaming viewing hours. In Apple’s favor is its quality — as the iPhone currently beats Android phones in every quality category. As streaming publishers expand into newer, less mature streaming markets outside of North America, optimizing the streaming experience for the android mobile device market will be of increasing importance.

Methodology

Conviva’s State of Streaming series is the largest cross-platform comparison of streaming data measuring ongoing, real-time, sessionized streaming data at Internet-scale.

Data analyzed for the Q2 2022 State of Streaming report was primarily collected from Conviva’s unique proprietary sensor technology. Currently embedded in 3.3 billion streaming video applications, it measures more than 500 million unique viewers watching 180 billion streams per year and nearly 2 trillion real-time transactions per day across more than 180 countries. The Internet-scale census-measurement is deployed from a full-stack censor that is not sampled, but validated, cleaned, enriched, standardized and sessionized. Continuous, real-time monitoring sessionizes streaming events, state timelines and meta data into viewer-led sessions. This more accurately reflects viewers’ real-world experiences.

The social media data, collected from the Streaming Publishers leaderboard list within Conviva Social Insights, consists of data from 100 accounts, over 7,500 million posts, and over 30 million engagements across Facebook, Instagram, Twitter, TikTok and YouTube between Q2 2021 and Q2 2022.

Year-over-year comparisons were normalized at the customer level for accurate representations of industry growth.

Get a copy of Conviva’s Q2 State of Streaming Report

About Conviva

Conviva is the only global streaming analytics platform for big data that collects, standardizes, and puts trillions of streaming data points in context, in real time. With Conviva, streaming businesses can understand real-world human experiences within seconds of observation and take action to grow their business ahead of the competition.

The Conviva platform provides comprehensive, continuous, census-level measurement through real-time, server side sessionization at scale. It includes first-of-its kind-innovations like time-state analytics and AI automated data modeling. Using a single full stack sensor at the source, coupled with a single big data pipeline, Conviva’s 60+ patent platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock incredible opportunity with streaming analytics. To learn more, visit www.conviva.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005099/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye